|Articles|April 11, 2022
- Pharmaceutical Executive-04-01-2022
- Volume 42
- Issue 4
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Seven Lessons I Learned Working at a Biotech Startupover 4 years ago
Next-Gen Partnerships: The Ascent of Advanced Therapiesover 4 years ago
Advantage Pharma: Capitalizing on Workforce Lessonsover 4 years ago
Diversity in Action: Q&A With Reshma Kewalramaniover 4 years ago
Diversity in Action: Q&A With Bob McMahonover 4 years ago
A Dogged Devotionover 4 years ago
Surviving Biotech’s Longest and Steepest Bear Market Everover 4 years ago
The Case for Elevating a Brand’s Price Propositionover 4 years ago
The Impact of Hybrid Workplace Decisions On DE&I DynamicsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors
2
Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report
3
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies
4
Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience
5